Novartis Announces EC Approvals for Cosentyx to Treat Patients with Ankylosing Spondylitis, Psoriatic Arthritis

by Charles Gross, Benzinga Editor
November 23, 2015 4:12 AM | 16 seconds read |
Novartis NVS announced today that the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). For AS, this is the first new treatment advance in 16 years since the development of the See full press release
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!